Aurora Cannabis (TSE:ACB) Issues Quarterly Earnings Results
by Doug Wharley · The Cerbat GemAurora Cannabis (TSE:ACB – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported C($0.07) earnings per share for the quarter, FiscalAI reports. The firm had revenue of C$67.55 million for the quarter. Aurora Cannabis had a negative net margin of 12.13% and a negative return on equity of 7.25%.
Aurora Cannabis Price Performance
Shares of Aurora Cannabis stock traded up C$0.12 during trading on Thursday, reaching C$4.18. 285,110 shares of the stock traded hands, compared to its average volume of 398,696. The company has a debt-to-equity ratio of 4.66, a current ratio of 5.94 and a quick ratio of 2.48. The company has a market capitalization of C$258.92 million, a price-to-earnings ratio of -1.95 and a beta of 0.25. Aurora Cannabis has a 52-week low of C$3.59 and a 52-week high of C$9.33. The business has a fifty day simple moving average of C$4.12 and a two-hundred day simple moving average of C$4.65.
Analyst Ratings Changes
Several analysts have recently commented on the stock. Canaccord Genuity Group decreased their price objective on shares of Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. TD cut their price target on Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating for the company in a research note on Friday, June 12th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of C$7.17.
Get Our Latest Research Report on ACB
Aurora Cannabis Company Profile
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
Recommended Stories
- Five stocks we like better than Aurora Cannabis
- Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next?
- Boeing’s Comeback Is Building Momentum—Is It Real?
- Blueprint for a Banking Fortress: Circle Redraws the Map
- Bed Bath & Beyond Renovates: The Neighborhood Blueprint